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Extended Abstract
Introduction: The first description of p53 protein is in 1979 and
since that time there have been more than 35 000 papers published on
this topic. However even after 30 years after its discovery, it is still
somewhat of a mystery. The gene encodes transcription factor p53
is TP53, one of the most commonly altered genes in human cancers.
P53 protein plays a central role to regulate cell cycle progression, dif-
ferentiation, senescence, DNA repair, and apoptosis. In response of
DNA damage or other stress signals, p53 activity is up-regulated
and a series of biological events cascade is initiated that eventually
results in prevention of tumor development and expansion. Recent
studies showed, about 50% of human cancers have p53 mutation
but the frequency varies considerably between cancer types, ranging
from ~10% in hematopoietic malignancies to 50e70% in ovarian,
colorectal and head and neck cancers. Mutations in p53 dissolve its
normal tumor suppressor functions finally contributing to the survival
and/or amplification of aberrant cells with poorly differentiated phe-
notypes. Cancer cells with mutant p53 are associated more aggressive
disease, increased resistance to radiation therapy and chemotherapy,
with poor prognosis of the disease.
Dominant negative mutation of TP53 gene: The presence of
p53 mutation in cell does not necessarily mean it loses p53 activity,
when a cell has a wild type allele together with the mutant one. In
this heterozygous state it should be known that, this cell may con-
tain a trans dominant mutation with reduced p53 activity and then
confer a growth advantage and other tumorogenesis signs. Moreover,
p53 mutant cancer cells which contain a dominant-negative activity
or Gain Of Function (GOF) activity that inactives hetero-oligomers
of the mutants with the wild-type protein. Dominant-negative p53
mutation results in the total abrogation of p53 protein function,
even if cells still have wild-type protein expression. Increasing evi-
dence showed that many p53 mutant cells also gain new oncogenic
properties that are independent from wild-type one. p53 mutants that
promote tumor progression or/and resistance to therapies become
the most common prognostic marker for both tumor recurrence
and death caused by cancer. These mutation reduce the ability of
the wild type p53 to bind to its target gene responsive element.
For example, in one study, mutant TP53 was found in 24 of 92
(26.1%) endometrial cancers, in which 14 cases showed dominant-
negative activity that was associated with progressed stages, non
endometrioid type tumors. It showed, the presence of a dominant
negative mutant p53 was related to poor outcomes, suggesting that
dominant negative mutant TP53 should play a pivotal role in the
progression of endometrial cancer.
TP53 cancer gene therapeutic way: On the result of many
researches that p53 inactivation is common in human cancers, it
may be assumed that reactivation of p53 and functional restoration
of the p53 tumor suppressor pathway is a potential and detrimental
therapeutic way against cancer. Gene therapy using wild-type p53,delivered by adenovirus vectors, is now widespread and other bio-
logic approaches like the development of oncolytic viruses designed
to replicate and kill only p53 defective cells. The other way is the
development of siRNA and antisense RNA's that activate p53 by
inhibiting the function of the negative regulators Mdm2, MdmX,
and HPV E6 is effective too. In conclusion Adenovirus-based p53
gene therapy as well as using small molecules include PRIMA that
can restore the transcriptional function to mutant p53 cell, or NUT-
LIN and RITAwhich interfere with MDM2-directed p53 degradation,
have been tested in a preclinical stage and some of these approaches
are currently in clinical development.
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Extended Abstract
Introduction: Breast cancer is the most common cause of malig-
nancy and cancer mortality among women in the less developed
(LDCs) and more developed (MDCs) countries worldwide. Global sta-
tistics indicate the annual incidence of breast cancer is increasing and
this is happening faster in countries with a low incidence rate of breast
cancer. Both environmental and genetic factors are involved in the risk
of breast cancer. Genetic risk factors such as variations in TOX3 which
contribute to the liability play an important role in the development of
the disease. In regard to the latter, genome wide association studies
(GWAs) has identified low penetration but high frequency disease-
associated single nucleotide polymorphisms (SNP) in a number of
genes, such as the HMG-box nuclear protein TOX high mobility group
box family member 3 (TOX3). TOX3, also known as TNRC9, is a
non-histone chromatin protein including anuclearlocalization signal
(NLS) and a high mobility group (HMG)-box domain followed by a
C-terminal polyglutamine stretch. The HMG-box super family is
described by a ~80 amino acid DNA-binding domain, and individual
members function such as regulation of gene expression, chromatin
remodeling, DNA repair, and genomic stability.
Previous data indicated that TOX is a sequence-independent
HMG-box DNA-binding protein.TOX3 maps to chromosome 16q12
and consists of seven exons. TOX3 is a region regularly lost in breast
cancers and is involved in the risk of spreading breast cancer. How-
ever, there is little data on TOX3 and breast cancer although TOX3
has profound effects on regulation of cellular activity during initia-
tion, maintenance, or developing of cancer.
TOX3 is highly expressed in the central nervous system (CNS), in
the ileum, and within the brain in the frontal and occipital lobe in nor-
mal human tissues as well as in breast tumor at a higher level than in
normal tissue. TOX3 risk-allele carriers have been reported to develop
more lobular breast tumors, and patients with this SNP who develop
luminal A (LumA) breast tumors have shorter overall survival.
TOX3 has calcium-dependent transcriptional activity and is a co-fac-
tor of cAMP response element (CRE)-binding protein (CREB) and
CREB-binding protein (CBP). RNAi-mediated knockdown of the
endogenous TOX3 resulted in significant reduction of calcium-
induced c-fos expression and complete inhibition of calcium
